title: [Imatinib mesylate-induced acute cytolytic hepatitis].
authors.forename: Pierre
authors.initials: P
authors.lastname: Rocca
authors.forename: Saïd
authors.initials: S
authors.lastname: El Jastimi
authors.forename: Jacques
authors.initials: J
authors.lastname: Troncy
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Alexandra
authors.initials: A
authors.lastname: Boucher
authors.forename: Thierry
authors.initials: T
authors.lastname: Vial
authors.forename: Christian
authors.initials: C
authors.lastname: Trépo
authors.forename: Fabien
authors.initials: F
authors.lastname: Zoulim
mesh_terms: D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate